Navy@3x
Navy@3x

Oxular

2 x Triesence® doses; nearly one year of response

Latest-3, news / By

Oxular’s Senior Medical Advisor, Prof. Marc de Smet, presented on “Managing CME via the Suprachoroidal Space” at the December 2021 IOIS Conference. His talk included an update on a hard-to-treat postsurgical macular edema patient. The Oxulumis® posterior suprachoroidal microcatheter was used under compassionate use for the administration of Triesence®, an approved triamcinolone acetonide suspension. The …

2 x Triesence® doses; nearly one year of response Read More »

Drug Delivery OIS presentation

Latest-2, news / By

Oxular’s Chief Scientific Officer, Ron Yamamoto, shared an overview of Oxular’s drug delivery formulations at the OIS Drug Delivery meeting. You can watch the entire talk below, to find out more about our long-lasting drug formulations – including a first look at our micelle technology designed for targeted, local delivery of chemotherapeutic agents in the …

Drug Delivery OIS presentation Read More »

Oxular presents at Eyecelerator

Latest-1, news / By

Our CEO, Tom Cavanagh, presented an overview of Oxular’s retinal therapeutics platform at Eyecelerator, during AAO 2021. It was a pleasure to share this update, with a specific focus on OXU-001, Oxular’s lead program investigating a long-lasting, suprachoroidally administered treatment for DME. You can read Tom’s presentation below. Play Previous Next

Oxular in Retina Today

news / By

Oxular was mentioned in this great article by Dr. Sivaprasad in Retina Today, on the promise of reduced treatment burden for DME patients via sustained-release steroids. Oxular is a key innovator in long-lasting retinal treatments and precise suprachoroidal space delivery, and some of the advantages behind our approach are highlighted here. Simply put, we believe …

Oxular in Retina Today Read More »

Oxular raises $37 million

news / By

Led by specialist life sciences investor, Forbion Investment will fund Phase 2 human clinical studies evaluating Oxular’s 12-month treatment for diabetic macular edema, and accelerate development of early-product pipeline   OXFORD, UK, 1 March 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announced that it has completed a $37 million (£27 million) …

Oxular raises $37 million Read More »

Dr. Jatinder Kapur appointed as VP of Quality

news / By

Appointment builds Oxular’s team as it prepares to enter human clinical studies evaluating OXU-001 OXFORD, UK, 8 February 2021 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces that it has appointed Dr. Jatinder Kapur as Vice President of Quality. His primary responsibilities include establishing and managing the Company’s Quality Management System, …

Dr. Jatinder Kapur appointed as VP of Quality Read More »

Retinoblastoma treatment receives Rare Paediatric Disease and Orphan-Drug Designations

news / By

Provides further momentum for OXU-003 development programme   OXFORD, England, Oct. 12, 2020 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces it has received both Rare Paediatric Disease and Orphan Drug designations from the U.S. Food and Drug Administration (U.S. FDA) for OXU-003, the Company’s proprietary drug in development for the treatment of …

Retinoblastoma treatment receives Rare Paediatric Disease and Orphan-Drug Designations Read More »

Dr. Rafiq Hasan appointed as Non-Executive Director

news / By

Oxular Limited Appoints Dr. Rafiq Hasan as Non-Executive Director OXFORD, UK, 5 October 2020 – Oxular Limited (“Oxular”), a leading retinal therapeutics development company, today announces it has appointed Dr. Rafiq Hasan as a Non-Executive Director of the Company. Dr. Hasan gained his medical degree in London and has pursued a highly successful career in …

Dr. Rafiq Hasan appointed as Non-Executive Director Read More »

Scroll to Top